Cite
HARVARD Citation
Block, G. et al. (2021). Fibroblast growth factor 23 as a risk factor for cardiovascular events and mortality in patients in the EVOLVE trial. Hemodialysis international. 25 (1), pp. 78-85. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Block, G. et al. (2021). Fibroblast growth factor 23 as a risk factor for cardiovascular events and mortality in patients in the EVOLVE trial. Hemodialysis international. 25 (1), pp. 78-85. [Online].